Sten Eva, Skov Per Stahl, Andersen Sven B, Torp Anna Maria, Olesen Annette, Bindslev-Jensen Ulla, Poulsen Lars K, Bindslev-Jensen Carsten
Allergy Clinic, 7542, National University Hospital, Blegdamsvej 9, 2100 Copenhagen Ø, Denmark.
APMIS. 2004 Jan;112(1):21-8. doi: 10.1111/j.1600-0463.2004.apm1120104.x.
A large proportion of soybean cultivars grown in the USA are now genetically modified varieties and concern has been raised about the safety of these products for consumers. A study of the impact on allergenic potency in soybeans, comparable except for the newly introduced gene (CP4 EPSPS), was performed using soybean-sensitized patients. The allergenicity of 18 different (10 GM and 8 WT) soybean extracts was examined blindly by the following three methods: A) Sera from patients with specific IgE against soybean were used to determine concentrations inducing 50% RAST inhibition; B) Histamine release induced by the extracts was examined using blood from sensitized patients; C) SPT was performed on sensitized patients with all 18 extracts. All three methods showed variations in the allergenic potency between the individual extracts but allergenic potential was not affected by presence of the transgene. By using standard in vitro methods and SPT for determination of allergenicity we were not able to detect any significant difference in the allergenic potency between GM and WT soybeans.
美国种植的大部分大豆品种现在都是转基因品种,人们对这些产品对消费者的安全性表示担忧。使用对大豆过敏的患者进行了一项关于大豆致敏性影响的研究,除了新引入的基因(CP4 EPSPS)外,其他方面具有可比性。通过以下三种方法对18种不同的(10种转基因和8种野生型)大豆提取物的致敏性进行了盲测:A)使用对大豆具有特异性IgE的患者血清来确定诱导50%RAST抑制的浓度;B)使用致敏患者的血液检测提取物诱导的组胺释放;C)对所有18种提取物对致敏患者进行皮肤点刺试验。所有三种方法都显示出各个提取物之间致敏性的差异,但致敏潜力不受转基因存在的影响。通过使用标准的体外方法和皮肤点刺试验来测定致敏性,我们未能检测到转基因大豆和野生型大豆在致敏性方面有任何显著差异。